This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share

Company Overview - RAPT Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing oral small-molecule therapies for oncology and inflammatory diseases, leveraging a pipeline approach with candidates like RPT193 and FLX475 [5] - The company operates a biopharmaceutical business model aimed at advancing proprietary drug candidates through research, clinical development, and potential commercialization, targeting patients with unmet medical needs [8] Financial Metrics - As of market close on February 17, 2026, RAPT's stock price was $57.84, with a market capitalization of $955.95 million [4] - The company reported a net income of -$105.64 million (TTM) and experienced a one-year price change of 502.5% [4] Recent Developments - On February 17, 2026, OrbiMed Advisors acquired an additional 556,273 shares of RAPT, with an estimated transaction value of $17.28 million, bringing its total holding to 1,642,891 shares valued at $55.64 million [2][6] - RAPT announced an acquisition by GSK for $58 per share, approximately 75% above its stock price of $33.15 on December 31, indicating the high value placed on promising immunology assets [6][7] Drug Development Focus - RAPT is advancing drug candidates targeting inflammatory diseases and immune pathways, with a notable candidate being ozureprubart, aimed at preventing severe allergic reactions, addressing a significant health challenge affecting over 17 million people in the U.S. [7] - The company's strategic focus on immunology-based therapeutics positions it to compete in markets with high unmet medical needs and significant growth potential [5]